Beijing Hotgen Biotech Co., Ltd (688068.SH) subsidiary's innovative drug SGT003 injection has received the "Acceptance Notice" for clinical trial application.

Beijing Hotgen Biotech Co., Ltd (688068.SH) announced that its subsidiary Beijing Shunjing Biopharmaceutical Technology Co., Ltd. (referred to as "Shunjing Biopharmaceutical") has received the "Acceptance Notice" from the National Medical Products Administration for its independently developed innovative drug SGT003 injection. SGT003 injection is a novel bispecific antibody candidate drug developed based on Shunjing Biopharmaceutical's NexTreg technology platform. Its core innovation lies in accurately clearing tumor microenvironment regulatory T cells (Tregs) and activating anti-tumor immunity. This mechanism not only targets tumor tissues accurately, regulates the tumor microenvironment, and activates the body's natural immune response to tumor cells, but also reduces the immune activation-related toxic side effects of the already marketed anti-CTLA-4 antibody ipilimumab. It effectively covers a wide range of solid tumor patients who are resistant or ineffective to traditional treatments.